Life Sciences Venture Fund aMoon Closes Second Fund at $660 Million
The second fund will focus on mid to late-stage health companies in the domains of pharma, digital health, and medical technology
Hagar Ravet | 10:00 06.03.2019
Israel-based life sciences, healthcare, and technology venture capital firm aMoon is closing its second fund, aMoon II, at $660 million, the company announced Wednesday.
For daily updates, subscribe to our newsletter by clicking here.Reuters reported the fund had $600 million in commitments in January. AMoon reported a $250 million commitment from Credit Suisse AG in May.